Abstract
In 2008, the method of taking skin cells from people suffering from disease and transforming them into embryonic-like stem cells was heralded as the 'breakthrough of the year' by publications such as Time magazine. Two years on, so-called induced pluripotent stem (iPS) cells are just beginning to shed new light on disease biology. From day one of this burgeoning area of study, stem cell pioneer George Daley of Children's Hospital in Boston, who developed the first library of disease-specific iPS cells lines, has remained involved in this fast-paced field. Ahead of the June annual meeting of the International Society for Stem Cell Research (ISSCR) in San Francisco, Elie Dolgin spoke to Daley about when and how reprogrammed stem cells will deliver.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
